May we target double-membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
作者信息
Shahmohamadnejad Shiva, Nabavi Seyed Fazel, Habtemariam Solomon, Sarkar Kasturi, Sil Parames C, Dowran Razieh, Nabavi Seyed Mohammad
机构信息
Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
出版信息
Cell Biol Int. 2020 Sep;44(9):1770-1772. doi: 10.1002/cbin.11400. Epub 2020 Jun 23.
Abstract
摘要
相似文献
1
May we target double-membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?我们能否将双膜囊泡和氧化甾醇结合蛋白作为靶点来对抗新型冠状病毒肺炎感染？
Cell Biol Int. 2020 Sep;44(9):1770-1772. doi: 10.1002/cbin.11400. Epub 2020 Jun 23.
2
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.在新冠肺炎患者中停用洛匹那韦/利托那韦：药物相互作用效应的持续时间。
J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086. doi: 10.1093/jac/dkaa253.
3
Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.使用多梳蛋白抑制剂作为抗病毒药物靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）
Epigenomics. 2020 May;12(10):811-812. doi: 10.2217/epi-2020-0154. Epub 2020 Jun 4.
4
Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).洛匹那韦和利托那韦在2019冠状病毒病（COVID-19）住院患者中的药代动力学
Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.
5
β-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.用于治疗新冠肺炎的β-抑制蛋白偏向性血管紧张素II受体激动剂
Circulation. 2020 Jul 28;142(4):318-320. doi: 10.1161/CIRCULATIONAHA.120.048723. Epub 2020 May 15.
6
Can an Old Ally Defeat a New Enemy?一个老盟友能打败一个新敌人吗？
Circulation. 2020 Jul 28;142(4):315-317. doi: 10.1161/CIRCULATIONAHA.120.047830. Epub 2020 Jun 1.
7
The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?肾素-血管紧张素系统与新型冠状病毒2019感染：血管紧张素转换酶2受体的作用？
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926911. doi: 10.1177/1470320320926911.
8
Lopinavir pharmacokinetics in COVID-19 patients.洛匹那韦在新冠肺炎患者中的药代动力学。
J Antimicrob Chemother. 2020 Sep 1;75(9):2702-2704. doi: 10.1093/jac/dkaa195.
9
Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?内体溶酶体离子通道是否可能成为 SARS-CoV-2 的阿喀琉斯之踵？
Cell Calcium. 2020 Jun;88:102212. doi: 10.1016/j.ceca.2020.102212. Epub 2020 May 6.
10
The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.脂代谢在 COVID-19 病毒感染中的作用及其作为药物靶点的研究。
Int J Mol Sci. 2020 May 17;21(10):3544. doi: 10.3390/ijms21103544.
引用本文的文献
1
Drug discovery and development targeting the life cycle of SARS-CoV-2.针对新型冠状病毒生命周期的药物发现与开发。
Fundam Res. 2021 Mar;1(2):151-165. doi: 10.1016/j.fmre.2021.01.013. Epub 2021 Feb 1.
2
Research Advances on the Role of Lipids in the Life Cycle of Human Coronaviruses.脂质在人类冠状病毒生命周期中作用的研究进展
Microorganisms. 2023 Dec 28;12(1):63. doi: 10.3390/microorganisms12010063.
3
Reinfection and reactivation of SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的再感染和再激活
Future Virol. 2022 Sep. doi: 10.2217/fvl-2021-0212. Epub 2022 Sep 26.
4
Host factors: Implications in immunopathogenesis of COVID-19.宿主因素：在 COVID-19 免疫发病机制中的意义。
Pathol Res Pract. 2021 Dec;228:153647. doi: 10.1016/j.prp.2021.153647. Epub 2021 Oct 12.
5
Lipid-based therapies against SARS-CoV-2 infection.针对 SARS-CoV-2 感染的脂质体疗法。
Rev Med Virol. 2021 Sep;31(5):1-13. doi: 10.1002/rmv.2214. Epub 2021 Jan 13.
6
Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG.三名新冠肺炎患者针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）结构蛋白的纵向抗体动态显示IgA、IgM和IgG同时产生。
J Inflamm Res. 2021 Jun 14;14:2497-2506. doi: 10.2147/JIR.S313188. eCollection 2021.
7
Intracellular host cell membrane remodelling induced by SARS-CoV-2 infection in vitro.SARS-CoV-2 感染诱导的细胞内宿主细胞膜重塑。
Biol Cell. 2021 Jun;113(6):281-293. doi: 10.1111/boc.202000146. Epub 2021 Mar 3.
8
Bis(monoacylglycero)phosphate, an important actor in the host endocytic machinery hijacked by SARS-CoV-2 and related viruses.双（单酰基甘油）磷酸酯，一种在宿主内吞机制中被 SARS-CoV-2 及相关病毒劫持的重要因子。
Biochimie. 2020 Dec;179:247-256. doi: 10.1016/j.biochi.2020.10.018. Epub 2020 Nov 5.
本文引用的文献
1
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.SARS-CoV-2 综述及正在进行的临床试验。
Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657.
2
National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management.国家传染病研究所“L. 斯帕兰扎尼”，意大利康复中心。新型冠状病毒肺炎临床管理建议。
Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543. eCollection 2020 Feb 25.
3
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
4
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
Differing activities of oxysterol-binding protein (OSBP) targeting anti-viral compounds.不同的固醇结合蛋白 (OSBP) 靶向抗病毒化合物的活性。
Antiviral Res. 2019 Oct;170:104548. doi: 10.1016/j.antiviral.2019.104548. Epub 2019 Jul 2.
7
Transient Compound Treatment Induces a Multigenerational Reduction of Oxysterol-Binding Protein (OSBP) Levels and Prophylactic Antiviral Activity.瞬时化合物处理诱导氧化固醇结合蛋白（OSBP）水平的多代减少和预防性抗病毒活性。
ACS Chem Biol. 2019 Feb 15;14(2):276-287. doi: 10.1021/acschembio.8b00984. Epub 2019 Jan 11.
8
Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP).依曲康唑的构效关系研究，一种广谱抑制微小核糖核酸病毒复制的药物，靶点为氧化固醇结合蛋白（OSBP）。
Antiviral Res. 2018 Aug;156:55-63. doi: 10.1016/j.antiviral.2018.05.010. Epub 2018 May 26.
9
Bridging the molecular and biological functions of the oxysterol-binding protein family.桥接氧化固醇结合蛋白家族的分子和生物学功能。
Cell Mol Life Sci. 2018 Sep;75(17):3079-3098. doi: 10.1007/s00018-018-2795-y. Epub 2018 Mar 13.
10
Antiviral activity of K22 against members of the order Nidovirales.K22 对套式病毒目成员的抗病毒活性。
Virus Res. 2018 Feb 15;246:28-34. doi: 10.1016/j.virusres.2018.01.002. Epub 2018 Jan 11.
Zotero 插件